TheEdgeResearch
Home / Stocks / VRCDF

Verici Dx plc (VRCDF)

OTC Healthcare Medical - Diagnostics & Research
$0.00 ▲ +0.00%
Market Cap
$6.9M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
1.17
52-Wk Range
0.003-2.91
CEO
Sara jane Barrington
Country
GB
Currency
USD

Verici Dx plc operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Penarth, TN, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $6.9M. On trailing twelve-month figures it carries a trailing P/E of -0.45, a net margin of -223.6%. Its beta of 1.17 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.45
Price / Sales
4.36
Price / Book
0.62
EV / EBITDA
-1.90
Gross margin
56.4%
Operating margin
-221.2%
Net margin
-223.6%
Return on equity
—
Debt / equity
0.14
Current ratio
2.82
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
19
IPO date
2022-05-27
Headquarters
Penarth, TN, GB
About Verici Dx plc

Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.

Comparable companies

Verici Dx plc is most often compared with the following Healthcare names:

ABDXFATBPFAVEFFCNPOFLVCLYLXXGFMGCLFMRVFFMXDHFSQIDF
More research on VRCDF
VRCDF technical analysis VRCDF TheEdge Score Compare against peers
Open full interactive analysis & DCF →